Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sabizabulin - Veru Healthcare

Next Previous
Drug Profile

Sabizabulin - Veru Healthcare

Alternative Names: APP-111; Bisindole; VERU-111

Latest Information Update: 10 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ohio State University; University of Tennessee Research Foundation
  • Developer University of Tennessee Research Foundation; Veru Healthcare
  • Class Anti-inflammatories; Antineoplastics; Antivirals; Imidazoles; Indoles; Ketones; Phenyl ethers; Small molecules
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Ebola virus infections; Smallpox
  • Preclinical Coronary artery disease; HER2 positive breast cancer
  • Suspended COVID 2019 infections; Influenza A virus H1N1 subtype; SARS-CoV-2 acute respiratory disease
  • No development reported Solid tumours
  • Discontinued Prostate cancer

Most Recent Events

  • 10 Apr 2025 Veru Healthcare plans a phase II trial for Coronary artery disease
  • 13 Feb 2025 Preclinical trials in Coronary artery disease in USA (PO), prior to February 2025
  • 13 Feb 2025 Veru Healthcare announces intention to submit an IND application to the US FDA for Coronary artery disease in the first half 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top